RA0104

antibody from Oursmab

Targeting: CD3E

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0104

Provider

Oursmab

Product name

Otelixizumab (Biosimilar Reference Antibody) (CD3E)

Antibody type

Monoclonal

Description

Otelixizumab (also known as TRX4 or ChAglyCD3) is a humanized, Fc-engineered monoclonal antibody that targets the CD3 epsilon (¦Å) chain of the T-cell receptor (TCR) complex. Its Fc region is engineered to reduce binding to Fc¦Ã receptors, thereby minimizing T-cell activation and cytokine release syndrome (CRS) compared to earlier anti-CD3 antibodies like muromonab-CD3 (OKT3). By binding to CD3, otelixizumab modulates T-cell function, inducing transient T-cell depletion, anergy, or immune tolerance.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.